231 related articles for article (PubMed ID: 21321296)
21. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort.
Green J; Czanner G; Reeves G; Watson J; Wise L; Beral V
BMJ; 2010 Sep; 341():c4444. PubMed ID: 20813820
[TBL] [Abstract][Full Text] [Related]
22. Optimal management of metastatic bone disease.
Major P
Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
[TBL] [Abstract][Full Text] [Related]
23. [Treatment of bone metastases with bisphosphonates].
Gremaud M; Delouche D; Monnerat C
Rev Med Suisse; 2006 Aug; 2(75):1861-6. PubMed ID: 16948423
[TBL] [Abstract][Full Text] [Related]
24. Use of intravenous bisphosphonates in older women with breast cancer.
Giordano SH; Fang S; Duan Z; Kuo YF; Hortobagyi GN; Goodwin JS
Oncologist; 2008 May; 13(5):494-502. PubMed ID: 18515734
[TBL] [Abstract][Full Text] [Related]
25. Bisphosphonates as treatment of bone metastases.
Holen I; Coleman RE
Curr Pharm Des; 2010; 16(11):1262-71. PubMed ID: 20166976
[TBL] [Abstract][Full Text] [Related]
26. Intravenous bisphosphonates for breast cancer: impact on patient outcomes and scientific concepts.
Gnant M
Breast Dis; 2011; 33(2):71-81. PubMed ID: 22142663
[TBL] [Abstract][Full Text] [Related]
27. [Clinical features and prognosis in 104 colorectal cancer patients with bone metastases].
Hong RX; Lin QJ; Luo J; Dai Z; Wang WN
Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):787-91. PubMed ID: 24378104
[TBL] [Abstract][Full Text] [Related]
28. The role of bisphosphonates in early- and advanced-stage breast cancer: have we finally optimized care?
Blanchette PS; Pritchard KI
Oncology (Williston Park); 2015 Jan; 29(1):23-30, 37. PubMed ID: 25595283
[TBL] [Abstract][Full Text] [Related]
29. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.
Fizazi K; Bosserman L; Gao G; Skacel T; Markus R
J Urol; 2013 Jan; 189(1 Suppl):S51-7; discussion S57-8. PubMed ID: 23234632
[TBL] [Abstract][Full Text] [Related]
30. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
[TBL] [Abstract][Full Text] [Related]
31. Bisphosphonates and breast cancer survival: a meta-analysis and trial sequential analysis of 81508 participants from 23 prospective epidemiological studies.
Liu Y; Zhao S; Zhang Y; Onwuka JU; Zhang Q; Liu X
Aging (Albany NY); 2021 Aug; 13(15):19835-19866. PubMed ID: 34375305
[TBL] [Abstract][Full Text] [Related]
32. Bisphosphonates and breast cancer incidence and recurrence.
Chlebowski RT; Col N
Breast Dis; 2011; 33(2):93-101. PubMed ID: 22142660
[TBL] [Abstract][Full Text] [Related]
33. Bisphosphonates in adjuvant setting for breast cancer: a review of the meta-analysis of bisphosphonates' effects on breast cancer recurrence presented in December 2013 at San Antonio Breast Conference.
Costa L
Curr Opin Support Palliat Care; 2014 Dec; 8(4):414-9. PubMed ID: 25319273
[TBL] [Abstract][Full Text] [Related]
34. A prospective study of bisphosphonate use and risk of colorectal cancer.
Khalili H; Huang ES; Ogino S; Fuchs CS; Chan AT
J Clin Oncol; 2012 Sep; 30(26):3229-33. PubMed ID: 22649131
[TBL] [Abstract][Full Text] [Related]
35. [Bisphosphonates in oncology].
Kurth AA; Heidenreich A; Diel I
Orthopade; 2007 Feb; 36(2):131-5. PubMed ID: 17252255
[TBL] [Abstract][Full Text] [Related]
36. Clinical value of bisphosphonates in cancer therapy.
Lüftner D; Henschke P; Possinger K
Anticancer Res; 2007; 27(4A):1759-68. PubMed ID: 17649770
[TBL] [Abstract][Full Text] [Related]
37. The Frequency of and Risk Factors for the Use of Bisphosphonates in the Adjuvant Setting of Primary Breast Cancer in Germany.
Fick EM; Katalinic A; Waldmann A
Cancer Res Treat; 2015 Oct; 47(4):747-56. PubMed ID: 25672584
[TBL] [Abstract][Full Text] [Related]
38. Bisphosphonates in breast cancer: a triple winner?
Mathew A; Brufsky A
Oncology (Williston Park); 2015 Jan; 29(1):37-9. PubMed ID: 25595284
[No Abstract] [Full Text] [Related]
39. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
von Moos R; Costa L; Gonzalez-Suarez E; Terpos E; Niepel D; Body JJ
Cancer Treat Rev; 2019 Jun; 76():57-67. PubMed ID: 31136850
[TBL] [Abstract][Full Text] [Related]
40. Role of bisphosphonates in postmenopausal women with breast cancer.
Gnant M
Cancer Treat Rev; 2014 Apr; 40(3):476-84. PubMed ID: 23906846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
